EUVIMEDEUVIMED entdecken
Crossref

Drug‐Induced Ductopenia in Two Prospective Registries: Favourable Outcomes and Late Recovery Despite Prolonged Cholestasis

Fernando Bessone iD, Nelia Hernandez iD, Maria Isabel Schinoni iD, Javier Brahm, Inmaculada Medina-Caliz iD, Daniela Chiodi, Mercedes Robles-Díaz, Ismael Alvarez-Alvarez iD, Hao Niu, Mercedes Cortese, Hugo Tanno, Maria Virginia Reggiardo und 6 weitere

Liver International · 2026-11 · 46 (11)

DOI: 10.1111/liv.70917 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Liver International, online erschienen am 11.10.2026. Verfasst von Fernando Bessone und 17 weiteren Autor:innen. Beteiligte Einrichtung: Facultad de Medicina, Hospital Provincial del Centenario, Universidad Nacional de Rosario, Rosario, Argentina. Hauptthemen laut MEDLINE: Cholestasis, Chemical and Drug Induced Liver Injury, Bile Ducts. Die Arbeit nennt 37 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background & Aims Drug‐induced ductopenia (DID) represents a rare histological phenotype of drug‐induced liver injury (DILI), typically associated with prolonged cholestasis and historically linked to poor outcomes. This study aimed to characterize the clinical presentation, histological features and outcomes of DID using data from the two prospective DILI registries.

Methods

Liver biopsy was performed in 298 patients from the Spanish DILI Registry and the LATINDILI Network. Ten cases (3.4%) fulfilled histological criteria for DID, defined as absence of interlobular bile ducts in more than 50% of portal tracts. Clinical characteristics, biochemical parameters, histological features and outcomes were analysed and compared with those of non‐ductopenic DILI cases.

Results

Patients with DID had a mean age of 47 ± 18 years, and 50% were female. Mixed liver injury predominated (50%). Causative drugs included amoxicillin‐clavulanate, ciprofloxacin, carbamazepine, sertraline, ibuprofen, droxicam, captopril, metformin, ticlopidine and stanozolol. All DID cases had jaundice, and rash was more frequent (40%) compared with 9.4% in non‐ductopenic DILI patients ( p = 0.013). Total bilirubin was significantly higher in DID (median 12 mg/dL vs. 6.6 mg/dL in non‐ductopenic DILI patients; p = 0.027). Histology revealed bile duct loss accompanied by cholestasis, portal inflammation, ductular reaction, fibrosis and occasional interface hepatitis. Despite marked cholestasis, no deaths or liver transplantation occurred in DID cases and biochemical recovery was achieved in most patients. Median follow up was 156 and 116 days in patients with DID and non‐ductopenic DILI cases, respectively.

Conclusions

DID is an uncommon phenotype of DILI, characterized by marked hyperbilirubinemia and a frequent association with hypersensitivity features. Most cases exhibited moderate liver injury and followed a benign, reversible clinical course, with no reports of poor outcome. However, delayed recovery was observed in a subset of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisChemical and Drug Induced Liver InjuryBile DuctsHumansFemaleMiddle AgedMaleRegistriesProspective StudiesSpainAdultBiopsyLiverAged

Stichwörter der Autor:innen

cholestasischronic DILIdrug‐induced liver injuryductopeniahepatotoxicityvanishing bile duct syndrome

Autor:innen und Institutionen

  • Facultad de Medicina, Hospital Provincial del Centenario, Universidad Nacional de Rosario, Rosario, Argentina.
  • Unidad Académica de Gastroenterología, Universidad de la República (UdelaR), Montevideo, Uruguay.
  • Universidad Federal de Bahia, Salvador de Bahia, Brazil.
  • Clínica Universidad de los Andes, Santiago de Chile, Chile.
  • Gastroenterology Department, Malaga Biomedical Research Institute (IBIMA Plataforma BIONAND), Hospital Universitario Virgen de la Victoria, University of Málaga, Málaga, Spain.
  • Centro de Investigación Biomédico en red Enfermedades Hepáticas y Digestivas (CIBERehd), Madrid, Spain.

ORCID-Profile: Fernando Bessone, Nelia Hernandez, Maria Isabel Schinoni, Inmaculada Medina-Caliz, Ismael Alvarez-Alvarez, Andrea Jimenez, Maria Isabel Lucena, Raul Jesus Andrade

Förderung

  • Instituto de Salud Carlos III

Zitieren

APA

Bessone, F., Hernandez, N., Schinoni, M. I., Brahm, J., Medina-Caliz, I., Chiodi, D., Robles-Díaz, M., Alvarez-Alvarez, I., Niu, H., Cortese, M., Tanno, H., Reggiardo, M. V., Tanno, F., Paraná, R., Fassio, E., Jimenez, A., Lucena, M. I., & Andrade, R. J. (2026). Drug‐Induced Ductopenia in Two Prospective Registries: Favourable Outcomes and Late Recovery Despite Prolonged Cholestasis. Liver International, 46(11). https://doi.org/10.1111/liv.70917

Vancouver

Bessone F, Hernandez N, Schinoni MI, Brahm J, Medina-Caliz I, Chiodi D, et al. Drug‐Induced Ductopenia in Two Prospective Registries: Favourable Outcomes and Late Recovery Despite Prolonged Cholestasis. Liver International. 2026;46(11). doi:10.1111/liv.70917

BibTeX
@article{Bessone2026,
  author = {Bessone, Fernando and Hernandez, Nelia and Schinoni, Maria Isabel and Brahm, Javier and Medina-Caliz, Inmaculada and Chiodi, Daniela and Robles-Díaz, Mercedes and Alvarez-Alvarez, Ismael and Niu, Hao and Cortese, Mercedes and Tanno, Hugo and Reggiardo, Maria Virginia and Tanno, Federico and Paraná, Raymundo and Fassio, Eduardo and Jimenez, Andrea and Lucena, Maria Isabel and Andrade, Raul Jesus},
  title = {Drug‐Induced Ductopenia in Two Prospective Registries: Favourable Outcomes and Late Recovery Despite Prolonged Cholestasis},
  journal = {Liver International},
  year = {2026},
  volume = {46},
  number = {11},
  doi = {10.1111/liv.70917}
}
Kostenlos starten →